Madrid, Spain

Pablo Manuel Avilés Marín

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2012-2023

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Pablo Manuel Avilés Marín: Innovator in Cancer Treatment

Introduction

Pablo Manuel Avilés Marín is a prominent inventor based in Madrid, Spain. He has made significant contributions to the field of oncology through his innovative research and development of cancer treatments. With a total of 3 patents, his work focuses on combination therapies and specific treatments for multiple myeloma.

Latest Patents

Pablo's latest patents include groundbreaking inventions aimed at improving cancer treatment. One of his notable patents is titled "Combination therapy with an antitumor alkaloid." This invention relates to the combination of PM01183 with various anticancer drugs, including platinum coordination complexes, antimetabolites, and other agents. The use of these combinations is intended to enhance the effectiveness of cancer treatments. Another significant patent is focused on "Multiple myeloma treatments," which provides methods for treating cancer using the compound PM00104, specifically targeting multiple myeloma.

Career Highlights

Pablo Manuel Avilés Marín is associated with Pharma Mar, S.A., a company dedicated to the development of innovative therapies for cancer treatment. His work at Pharma Mar has positioned him as a key player in the pharmaceutical industry, contributing to advancements in cancer therapies.

Collaborations

Pablo has collaborated with esteemed colleagues, including Enrique Maria Ocio and Atanasio Pandiella. These collaborations have further enriched his research and development efforts in the field of oncology.

Conclusion

Pablo Manuel Avilés Marín is a distinguished inventor whose work in cancer treatment has the potential to significantly impact patient care. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…